Association of Neighborhood-Level Household Income With 21-Gene Recurrence Score and Survival Among Patients With Estrogen Receptor–Positive Breast Cancer
Sign Up to like & getrecommendations! Published in 2023 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2023.0179
Abstract: Key Points Question Do household income levels factor into 21-gene recurrence score (RS) and mortality among patients with estrogen receptor (ER)-positive breast cancer? Findings In this cohort study involving 119 478 women, low income was associated… read more here.
Keywords: household income; recurrence score; patients estrogen; gene recurrence ... See more keywords
De‐escalation of five‐year adjuvant endocrine therapy in patients with estrogen receptor‐low positive (immunohistochemistry staining 1%‐10%) breast cancer: Propensity‐matched analysis from a prospectively maintained cohort
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34155
Abstract: The standard 5 years of endocrine therapy has demonstrated additional benefits compared with short‐term (2‐3 years) treatment in patients with estrogen receptor (ER)‐positive breast cancer; however, data specific to ER‐low positive breast cancer (1%‐10% by… read more here.
Keywords: estrogen receptor; breast cancer; patients estrogen; endocrine therapy ... See more keywords
Comparison of the Modified Immunohistochemical Marker Score and 21-Gene Recurrence Score Assay in Patients with Estrogen Receptor-Positive Breast Cancer
Sign Up to like & getrecommendations! Published in 2021 at "Oncology"
DOI: 10.1159/000521287
Abstract: Introduction: Not only the 21-gene recurrence score (RS) assay but also online prognostic tools and immunohistochemical prognostic models predict chemotherapy benefits for women with early breast cancer (BC). Multigene assays, including Oncotype DX, are expensive… read more here.
Keywords: breast cancer; patients estrogen; score; recurrence score ... See more keywords